All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Priority Review to Fruquintinib for Previously Treated mCRC

May 25th 2023

The FDA has granted priority review to the new drug application seeking the approval of fruquintinib for use in the treatment of adult patients with previously treated metastatic colorectal cancer.

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

Health Systems Model Disparities in Leukemia Survival in Low-Income Countries

May 25th 2023

The implementation of health systems strengthening models appeared to be effective in reducing disparities in leukemia survival among patients in low- and middle-income countries.

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

May 25th 2023

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.

Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDS

May 25th 2023

Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

May 25th 2023

Minimally invasive distal pancreatectomy was found to be a safe and effective alternative to that of open distal pancreatectomy in patients with resectable pancreatic cancer, confirmed by a noninferior radical resection rate, lymph node yield, and comparable survival data.

Advances in Precision Medicine Propel Personalized GI Cancer Care

May 25th 2023

Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.

Powerful Chemotherapy Drug Reaches Brain Tumors Using Novel Ultrasound Technology

May 25th 2023

Northwestern Medicine scientists report results of the first in-human clinical trial in which they used a novel, skull-implantable ultrasound device to open the blood-brain barrier and repeatedly permeate large, critical regions of the human brain to deliver chemotherapy that was injected intravenously.

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

May 25th 2023

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

Clinical Trials in Endometrial Cancer Need Improved Diversity to Address Rising Mortality Rates

May 25th 2023

Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

May 25th 2023

The combination of sitravatinib and nivolumab did not meet the primary end point of overall survival compared with docetaxel as second- or third-line treatment for patients with advanced nonsquamous non–small cell lung cancer who progressed on prior chemotherapy and immune checkpoint inhibitor therapy.

Clinical Updates for the Management of Lung Cancer Brain Metastases

May 25th 2023

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

May 24th 2023

Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.

Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI Cancers

May 24th 2023

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

Ongoing Investigation of RLY-4008 Highlights Evolving Treatment Options for FGFR2+ Cholangiocarcinoma

May 24th 2023

R. Kate Kelley, MD, details the ongoing investigation of RLY-4008 for patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, other ongoing investigations in cholangiocarcinoma, and the importance of molecular testing to drive treatment decisions in this population.

Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting

May 24th 2023

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

May 24th 2023

Voruciclib monotherapy and in combination with venetoclax demonstrated clinical activity and was well tolerated with no significant myelosuppression in heavily pretreated patients with relapsed/refractory acute myeloid leukemia or B-cell malignancies, according to initial data from a phase 1 trial.

NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera

May 24th 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

May 24th 2023

CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.

Milademetan Plus ONC201 Could Represent Synergistic Combination in MDM2-overexpressing Solid Tumors

May 24th 2023

Ilyas Sahin, MD, details the preclinical findings from the study and highlighted how these data could help inform future studies for the treatment of patients with MDM2-overexpressing solid tumors.